Larimar Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held virtually by Larimar Therapeutics, Inc. on May 13, 2025. The record date for the meeting was March 27, 2025, with 64,027,892 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Three proposals were submitted to stockholders, all of which were approved:
- Proposal 1 (Election of Class II Director): Thomas E. Hamilton was elected to the Board of Directors. He received 46,479,322 votes for, with 4,326,129 votes withheld and 6,865,481 broker non-votes.
- Proposal 2 (Advisory Executive Compensation): Stockholders approved the 2024 compensation of named executive officers. The vote was 49,187,132 for, 1,445,631 against, and 172,688 abstentions.
- Proposal 3 (Ratification of Auditors): The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the 2025 fiscal year was ratified. The vote was 57,657,322 for, 10,851 against, and 2,759 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the results of the annual meeting.
Key Facts for Investor Verification
- Thomas E. Hamilton's term as a Class II director extends until the 2028 Annual Meeting.
- PricewaterhouseCoopers LLP is confirmed as the auditor for the 2025 fiscal year.
- Executive compensation for 2024 received significant stockholder support with over 97% of votes cast in favor (excluding abstentions and non-votes).
- Broker non-votes totaled 6,865,481 shares for the director election and executive compensation proposals.